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Hilar cholangiocarcinoma (CCA) is a difficult malignancy to treat surgically because of its anatomical location and its frequent
association with primary sclerosing cholangitis. Neoadjuvant chemoradiotherapy followed by liver transplantation in lymph
node–negative patients has been advanced by select liver transplant centers for the treatment of patients with unresectable dis-
ease. This approach has most commonly used external-beam radiotherapy in combination with biliary brachytherapy and 5-
fluorouracil–based chemotherapy. Our center recently embarked on a protocol using stereotactic body radiation therapy
(SBRT) followed by capecitabine in lymph node–negative patients until liver transplantation. We, therefore, retrospectively
determined the tolerability and pathological response in this pilot study. During a 3-year period, 17 patients with unresectable
hilar CCA were evaluated for treatment under this protocol. In all, 12 patients qualified for neoadjuvant therapy and were treated
with SBRT (50-60 Gy in 3-5 fractions over the course of 2 weeks). After 1 week of rest, capecitabine was initiated at 1330 mg/
m2/day, and it was continued until liver transplantation. During neoadjuvant therapy, there were 35 adverse events in all, with
cholangitis and palmar-plantar erythrodysesthesia being the most common. Capecitabine dose reductions were required on 5
occasions. Ultimately, 9 patients were listed for transplantation, and 6 patients received a liver transplant. The explant pathology
of hilar tumors showed at least a partial treatment response in 5 patients, with extensive tumor necrosis and fibrosis noted.
Additionally, high apoptotic indices and low proliferative indices were measured during histological examinations. Eleven
transplant-related complications occurred, and the 1-year survival rate after transplantation was 83%. In this pilot study, neoad-
juvant therapy with SBRT, capecitabine, and liver transplantation for unresectable CCA demonstrated acceptable tolerability.
Further studies will determine the overall future efficacy of this therapy. Liver Transpl 20:81-88, 2014.VC 2013 AASLD.
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The treatment of hilar cholangiocarcinoma (CCA) is
most effective when hepatic resection is performed
and negative surgical margins can be achieved.
Unfortunately, only 35% to 40% of presenting patients
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are able to undergo resection because of bilateral vas-
cular/biliary involvement, metastatic disease, or
underlying hepatic disease, including primary scleros-
ing cholangitis (PSC).1 Pioneering work by the Mayo
Rochester group demonstrated the feasibility and effi-
cacy of using neoadjuvant chemoradiotherapy, stag-
ing for negative hilar lymph nodes, and then
orthotopic liver transplantation (OLT).2,3 This thera-
peutic approach to hilar CCA has resulted in survival
rates that are similar to the rates for patients under-
going OLT for other forms of liver disease.4 Therefore,
in 2008, the United Network for Organ Sharing began
to accept the listing of patients with unresectable
hilar CCA as long as the centers had an established
protocol using neoadjuvant chemoradiotherapy along
with a demonstration of a negative lymph node status
for metastatic disease.
Recent neoadjuvant chemoradiotherapy protocols
have primarily used a combination of external-beam
radiotherapy (given over several weeks) and brachy-
therapy via biliary catheterization to a total dose of 45
to 55 Gy.4 After radiation therapy, chemotherapy has
traditionally been based on a 5-fluorouracil infusion
followed by capecitabine. Our center has developed
the novel use of stereotactic body radiation therapy
(SBRT) in the treatment of hepatic malignancies.5,6
Safety and efficacy have been demonstrated for these
cancers often in many patients with underlying liver
disease or cirrhosis.5,7 SBRT has the advantage of
delivering high doses of radiotherapy to confined
areas while sparing surrounding structures or paren-
chyma from toxicity. SBRT, therefore, has the added
advantage of allowing a shorter treatment course,
often in 3 to 5 fractions in a 2-week period.
We therefore, decided to use our center’s expertise in
SBRT, a recently developed therapy for the treatment
of hepatic malignancies, in our neoadjuvant chemora-
diotherapy protocol (followed by OLT) for patients with
unresectable CCA and lymph node–negative disease.
The aims of this pilot study were to determine (1) the
overall tolerability of this regimen with respect to side
effects and adverse events and (2) the pathological
response through histological evaluations of explanted
transplant specimens. We also sought to examine toler-
ability as it was related to reaching successful trans-
plantation and any influence on transplant related
complications. Although significant adverse events
(SAEs) occurred, these were often well tolerated as 9
patients were listed and 6 of these patients have
undergone transplantation to date. Significant tumor
responses were noted on suggesting that this regimen
utilizing SBRT results in acceptable tumor control with




This retrospective study was approved by the Univer-
sity of Michigan institutional review board. Patients
with hilar CCA were identified through a review by
our multidisciplinary liver tumor clinic and board.
Patients’ diagnoses and treatments followed an exist-
ing transplant committee treatment protocol at the
University of Michigan. The diagnosis and inclusion
criteria were similar to those described by the Mayo
Rochester group previously.2,3 Patients were required
to have a malignant-appearing hilar biliary stricture
above the cystic duct and a carbohydrate antigen 19-
9 level greater than 100 ng/mL, a transcatheter
biopsy/brush cytology positive for adenocarcinoma,
or an associated mass on cross-sectional imaging that
was 3.0 cm or less in its maximal radial diameter.
Patients whose tumors were determined to be unre-
sectable on the basis of bilateral vascular or biliary
involvement or underlying liver disease (PSC) were
further evaluated by our multidisciplinary liver trans-
plant committee. Staging included computed tomogra-
phy (CT) or magnetic resonance imaging (MRI) of the
abdomen and CT of the chest. Positron emission
tomography was used selectively for indeterminate
lesions noted on initial cross-sectional imaging.
Patients were excluded if they had any overt evidence
of distant disease or regional lymph node metastasis.
Patients were likewise excluded if there was any prior
attempt at surgical resection or open or percutaneous
biopsy or prior treatment. Finally, endoscopic ultra-
sound (EUS) with fine-needle aspiration of hilar lymph
nodes was routinely performed, and if the results
were positive, patients were excluded from entry into
the protocol.8
Neoadjuvant Protocol and Transplantation
Patients who were found to be acceptable transplant
candidates and met the inclusion criteria for the neoad-
juvant protocol were treated with SBRT: the total dose
of 50 to 60 Gy was divided into 3 to 5 fractions (10-20
Gy/fraction)5,6 in accordance with our routine institu-
tional practice. Briefly, patients underwent CT simula-
tion with a customized vacuum body mold. Active
breathing control was used to eliminate breathing-
related tumor motion. Tumors were delineated on MRI,
and these images were fused with CT images for plan-
ning. To account for setup variations, 5-mm radial
margins and 8-mm superior and inferior margins were
added to generate the planning target volume. SBRT
was delivered with 8 to 16 nonopposed, noncoplanar,
static 6- and 16-MV photon beams. The radiation dose
was prescribed to the isodose surface covering 99.5%
of the planning target volume (typically 75%-85% of the
maximum dose). Daily cone-beam CT was used before
each treatment for image guidance. SBRT was com-
pleted in 2 weeks, and after a 1-week rest, patients
were initiated on capecitabine (1330 mg/m2/day in 2
divided oral doses rounded to the nearest 500 mg). The
staging operation was performed 4 to 6 weeks after the
initiation of SBRT after a 3-day hold of capecitabine.
The staging operation was performed in a completely
laparoscopic or laparoscopy-assisted manner. An
examination for extrahepatic disease was performed
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along with hepatic ultrasound. Excisional biopsy of
hilar lymph nodes was performed, and samples were
subjected to permanent pathology. Patients were
removed from the protocol for any evidence of perito-
neal metastasis or lymph node metastasis. Capecita-
bine was reinitiated at discharge and continued until
transplantation. Capecitabine was held for a 1-week
rest every 6 weeks while patients were listed.
Once the final pathology was completed after the
staging operation, patients were listed for liver trans-
plantation. The regional review board was asked to
grant a Model for End-Stage Liver Disease exception
of 22 points9 with an additional 3-point increment if
the wait time went beyond 3 months. Staging CT
scans were repeated every 3 months to evaluate
patients for disease stability while they were on the
wait list. The transplant procedure was performed as
previously described, and care was taken to divide
hilar structures as distally as possible and to remove
any additional hilar lymph nodes.2,3 Frozen sections
were performed for the distal bile duct to determine
whether pancreaticoduodenectomy would be neces-
sary. A vena cava–sparing technique was used along
with a donor iliac artery conduit for donor hepatic
artery reconstruction to the recipient supraceliac
aorta to prevent arterial complications.10 Biliary
reconstruction was performed via hepaticojejunos-
tomy. Capecitabine was discontinued, and immuno-
suppression was initiated according to our center’s
standard protocol with a prednisone taper, mycophe-
nolate mofetil, and tacrolimus. Hepatic duplex was
performed on postoperative days 1, 7, and 21, and
subsequently, contrast-enhanced CT or MRI was per-
formed every 3 months after the operation for the first
year and every 6 months thereafter.
Patient Monitoring
One week after SBRT, capecitabine was initiated, and
patients were monitored weekly for signs of toxicity by
laboratory and symptom assessment. For patients
who experienced a clear treatment–related toxicity of
grade 2 or greater, capecitabine was held until grade
1 or less was achieved. Capecitabine was then
resumed with a daily dose reduction of 500 mg. All
adverse events were defined as those occurring after
the initiation of neoadjuvant therapy and were deter-
mined upon a retrospective review of the medical his-
tory, with SAEs defined as those that resulted in
hospitalization, an escalated level of care, or a signifi-
cant clinical intervention. An SAE related to cholangi-
tis was treated with urgent antibiotics and biliary
tube interrogation.
Tumor Histological Analysis
Tumor explants after transplantation were paraffin-
embedded and sectioned for routine hematoxylin and
eosin (H&E) staining, and they were reviewed by a
gastrointestinal pathologist. Additional serial sections
were deparaffinized in xylene and rehydrated in
descending alcohol concentrations, and this was fol-
lowed by heat-induced antigen retrieval via boiling in
a citrate buffer. Antibodies for cytokeratin 7 (CK7;
clone OV-TL 12/30, Dako, United States) and Ki-67
(clone MIB-1, Dako) were used for immunohistochem-
ical staining after the blockade of endogenous peroxi-
dase and protein according to the manufacturer’s
instructions.11,12 Biotinylated Link and streptavidin/
horseradish peroxidase (Dako) were subsequently
incubated, and this was followed by 3,30-diaminoben-
zidine chromogen incubation (Dako) for development.
Terminal deoxynucleotidyl transferase–mediated deox-
yuridine triphosphate nick-end labeling (TUNEL)
staining was performed according to the manufac-
turer’s procedure (ApopTag Plus peroxidase in situ
apoptosis kit, #S7101, Millipore, United States).
Slides from 2 to 3 representative areas in each tumor
specimen were examined at a magnification of 340,
and Ki-671 and TUNEL1 cells were determined for at
least 200 CK71 tumor cells per patient. Proliferative
indices (PIs) and apoptotic indices (AIs) were calcu-
lated as percentages of Ki-671 CK7 cells and TUNEL1
CK7 cells, respectively.13 Surgically resected tumors
that had not been subjected to neoadjuvant therapy
served as controls for this analysis.
RESULTS
Patient Presentation
Seventeen patients with unresectable hilar CCA were
evaluated for the neoadjuvant chemoradiotherapy
protocol and transplantation after a review by our
multidisciplinary liver tumor and transplant pro-
grams. The baseline demographics (Table 1) showed
that the majority of the patients were male; 24% of
the patients had PSC as an underlying etiology, and
71% had a de novo or no predisposing etiology. One
patient had an underlying type IV choledochal cyst.
Ten patients (59%) had a measurable mass on cross-
sectional imaging with an overall mean tumor
TABLE 1. Presentation of Patients With Unresectable
Hilar CCA
Evaluated patients (n) 17




De novo 12 (71)
Other 1 (6)
Mean mass size (cm)* 1.42 (0-3.2)
Mean carbohydrate antigen 19-9 level
(ng/mL)
429
Mass [n (%)] 10 (59)
Only brushing positive [n (%)] 5 (29)
PTC [n (%)] 13 (76)
*The range is shown in parentheses.
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diameter of 1.42 cm. Five patients (29%) had brush-
ings positive for adenocarcinoma on cholangiography
along with a malignant-appearing stricture as their
diagnostic criteria. Two patients had a malignant-
appearing stricture along with an elevated carbohy-
drate antigen 19-9 level as their only presenting diag-
nostic criteria.
Ultimately, 12 patients (71%) were able to start neo-
adjuvant therapy (Table 2 and Supporting Fig. 1); 5
patients were excluded from entering neoadjuvant
therapy because of positive findings on an EUS lymph
node aspirate (1 patient), peritoneal metastasis on
early diagnostic laparoscopy (3 patients), or newly
symptomatic coronary artery disease (1 patient). Diag-
nostic laparoscopy was performed for these patients
because of clinical concerns about a higher disease
stage despite initial eligibility according to cross-
sectional imaging and EUS screening.
Protocol Completion and Tolerability
Radiation therapy for a total dose of 50 to 60 Gy was
achieved in all 12 patients, although 1 patient was
treated with a non-SBRT protocol because of concern
about longitudinal extension; ultimately, this patient
had peritoneal metastases on later staging laparo-
scopy. The other 11 patients received SBRT in 3 to 5
fractions, and capecitabine was initiated as sched-
uled. During the neoadjuvant treatment, 35 adverse
events occurred after the initiation of therapy, with 14
of these being significant enough to be classified as
SAEs (Table 3). SAEs occurred in 6 patients (50% of
treated patients), with cholangitis related to PTC tube
dysfunction being the most significant and common
etiology. Other SAEs were related to dehydration (3
episodes) and occurred in the same patients with
cholangitis. The most common non-SAE adverse
events were palmar-plantar erythrodysesthesia (6
patients), diarrhea (2 patients), and wound infections
after the staging operation (2 patients). No other gas-
trointestinal toxicity such as gastritis or ulcer disease
was noted. In all, there were 5 dose reductions of
capecitabine among 4 patients. All 12 patients under-
went staging laparoscopy or laparoscopy-assisted
exploration and portal lymph node sampling 4 to 6
weeks after the completion of SBRT. One patient was
found to have peritoneal disease, and 2 patients were
found to have positive lymph nodes according to the
final pathological examination (Supporting Fig. 1).
Therefore, 9 patients were formally listed for trans-
plantation with Model for End-Stage Liver Disease
exception scores of 22 points. The need for elective
and urgent biliary interventions was common: a mean
of 7 such interventions were required per patient dur-
ing the treatment and transplant wait time period.
One patient was ultimately removed from the list
because of concerns about decreasing performance
status along with weight loss, and another was
removed at the time of exploration with transplant
intent when a peritoneal metastasis was identified.
Therefore, the dropout rate after neoadjuvant therapy
due to a positive staging operation (3 patients), dis-
ease progression (1 patient), or a lack of tolerability (1
patient) was 42%.
Transplantation and Tumor Responses
Ultimately, 6 patients underwent deceased donor
OLT, with 1 patient actively listed at the time of this
writing (Table 3). The mean and median wait times
were 92 and 88 days, respectively (range 5 29-201
days). The mean cold and warm ischemia times were
344 and 27 minutes, respectively. One patient
required a concomitant pancreaticoduodenectomy
secondary to an initially positive distal bile duct mar-
gin. All patients received a supraceliac aorta interposi-
tion graft to the hepatic artery with a donor iliac
conduit. There were 11 transplant-related complica-
tions in all (Table 3). One patient was free of any com-
plications. The 1-year survival rate was 83%, with 1
patient dying after discharge because of presumed
cardiovascular collapse 21 days after transplantation.
The median follow-up time was greater than 14
months to date. There were 2 re-explorations for
bleeding secondary to a pancreatic leak; however,
there were no vascular, biliary, or hepatic insuffi-
ciency complications to date. The median length of
stay after OLT was 12.5 days.
TABLE 2. Neoadjuvant Chemoradiotherapy and Transplant Protocol Completion
Evaluated patients (n) 17
Ruled-out patients (n) 5
Positive EUS [n (%)] 1 (6)
Early progression: peritoneal disease [n (%)] 3 (18)
New comorbidity [n (%)] 1 (6)
Patients undergoing neoadjuvant therapy (n) 12
Patients with positive staging laparoscopy [n (%)] 3 (25)
Lymph node 2
Peritoneal metastasis 1
Patients listed for transplantation [n (%)] 9 (75)
Removed from list (n) 2
Received transplant (n) 6
Waiting (n) 1
84 WELLING ET AL. LIVER TRANSPLANTATION, January 2014
Routine clinical pathological reviews of tumor
explants showed at least a partial response for 5 of
the 6 patients, with 1 patient histologically demon-
strating a complete response. One patient was a non-
responder. The responding patients showed evidence
of significant necrosis and fibrosis on routine histolog-
ical examinations (Fig. 1). Patients with a partial
response had only minute foci (<0.2 cm) of viable
tumor cells remaining. We, therefore, performed fur-
ther examinations with immunohistochemical stain-
ing, and we showed that in contrast to patients who
had undergone surgical resection without neoadju-
vant therapy (controls), all patients who had been
treated neoadjuvantly and then had undergone trans-
plantation had a low PI (Ki-671) among CK71 tumor
cells (Figs. 2 and 3 and Supporting Fig. 2; range 5
0%-17%). Additionally, a high AI (TUNEL1/CK71) was
noted among remaining tumor cells (range 5 2%-51%)
in comparison with untreated (control) patients. The 1
patient with a complete response according to the
clinical histological examination had an undetectable
PI but the highest AI among CK71 tumor cells at 51%
(Supporting Fig. 2). The mean gross tumor size at
explant was 1.95 cm. Three patients had evidence of
neurovascular invasion: one of these patients had a
positive lymph node, and another patient had a sub-
sequent peritoneal implant noted on the final pathol-
ogy report. Both of these patients ultimately suffered
from recurrence and succumbed to disease after sys-
temic therapy 16 and 30 months after transplanta-
tion. Four of the 6 explants (67%) were noted to have
perihilar cirrhosis or fibrosis in the liver parenchyma
not involved by tumor. Two of these patients did not
have a diagnosis of PSC and had de novo hilar CCA.
DISCUSSION
Hilar CCA continues to be a challenging treatment
problem because of the often distant and local extent of
the disease. It has been estimated that 30% of these
patients present with advanced disease, and as few as
50% of those with disease confined to the liver hilum
will undergo R0 (negative margin) resection because of
bilateral biliary and vascular invasion.1 Additionally,
many patients have underlying PSC, which further lim-
its safe resection. Although early experiences involved
the exploration of whether liver transplantation might
be a therapeutic option for patients with unresectable
disease,14 the Mayo Rochester group pioneered the use
of neoadjuvant chemoradiotherapy in addition to rigor-
ous surgical staging before transplantation, and the
overall results have been similar to those for transplan-
tation for other disease etiologies.2,3 The ability to
achieve R0 resection and the presence of negative
lymph nodes are the most significant positive prognos-
tic factors for the surgical therapy of hilar CCA.1,15,16
Consequently, an evaluation of lymph nodes using a
combination of EUS-guided biopsy and surgical
TABLE 3. Tolerability of Neoadjuvant Therapy and Transplant Outcomes
Total adverse events (n) 35
Total SAEs (n) 14
SAEs per patient (n)* 1 (0-6)
Total other adverse events (n) 21
Adverse events per patient (n)* 2 (0-8)
Most frequent adverse events [n/N (%) of treated patients]
Cholangitis 6/12 (50)
Palmar-plantar erythrodysesthesia 6/12 (50)
Diarrhea 2/12 (17)
Wound infection (after staging procedure) 2/12 (17)
Dose reductions (n) 5
Mean biliary interventions (n) 7
Total transplants (n) 6
Mean waiting time (days) 92
Mean cold ischemia time (minutes) 344
Mean warm ischemia time (minutes) 27
Median length of stay (days) 12.5
Posttransplant complications (n) 11
1-year survival (%) 83
Tumor explant pathology
Mean tumor size (cm) 1.95
Neurovascular invasion (n) 3
Positive lymph node (n) 1
Response [n/N (%)]
Complete response 1/6 (17)
Partial response 4/6 (67)
No response 1/6 (17)
*The range is shown in parentheses.
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staging is critically important in selecting patients for
this transplant therapy.8
The experience with neoadjuvant chemoradiother-
apy using external-beam radiation therapy, brachy-
therapy, and 5-fluorouracil–based chemotherapy has
shown significant tumor responses to date, but a sig-
nificant number of therapeutic sessions are required
to deliver this therapy. SBRT has the ability to con-
centrate the radiation dose to a confined anatomical
area over a shorter number of fractions and to mini-
mize adjacent toxicities. Our center has been a fore-
runner in the use of SBRT for a variety of hepatic
malignancies, and it has been shown to be safe and
effective, even in the presence of underlying liver dis-
ease.5,6 Therefore, we sought to build on this experi-
ence by using a combination of SBRT (in 5 fractions
or fewer) and subsequent oral capecitabine for the
neoadjuvant treatment of patients with unresectable
hilar CCA before transplantation. Our total dose of 50
to 60 Gy in 3 to 5 twice weekly treatments is, there-
fore, similar or more biologically intense than the
originally described protocol of an external beam
given in 30 fractions along with supplemental
brachytherapy.3,10
Figure 1. Histology of hilar CCAs after neoadjuvant therapy. Representative hilar tumors from patients with partial clinical pathologi-
cal responses after transplantation (n 5 3) were stained with H&E (magnification 340).
Figure 2. Immunohistochemistry for proliferating and apoptotic CCA cells. Images from 2 representative patients with partial patho-
logical responses are shown (top row, patient 2; middle row, patient 5). An untreated, surgically resected CCA is shown for comparison
(bottom row). Serial sections for H&E staining, CK7 staining for CCA cells, Ki-67 staining for proliferation, and TUNEL staining for apo-
ptosis are indicated, and the staining was performed as described in the Patients and Methods section. Arrows indicate dual-positive
TUNEL1/CK71 cells (magnification 340).
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The present analysis represents a pilot study
designed to examine our initial experience with this
algorithm and to determine overall tolerability. We
also sought to examine tumor responses histologically
in explants after transplantation. Overall, other than
the expected adverse events related to cholangitis and
the need for continuous biliary decompression, our
protocol was well tolerated. Over the course of our
experience, episodes of cholangitis requiring admis-
sion and urgent biliary interventions appeared to dis-
sipate, with the majority of episodes occurring in our
earlier patients and with 50% of our patients being
completely free of such episodes. It is possible that
the increasing coordination of our multidisciplinary
care during the course of our protocol accounted for a
gradual reduction in cholangitis-related events,
although it is difficult to generalize with a cohort of
this size. Palmar-plantar erythrodysesthesia was the
next most common adverse event associated with
capecitabine therapy; however, only 5 dose reductions
were necessary. One patient required removal from
the list because of a declining performance status
after a significant waiting time. No patients experi-
enced decompensation of liver disease after neoadju-
vant therapy. Therefore, the overall dropout rate due
to disease progression or a lack of tolerability was
somewhat comparable to the rate of previous experi-
ences: we experienced a dropout rate of 42%, whereas
other groups have experienced a 31% dropout rate.17
Care must be taken when comparisons are made
between this pilot study and other experiences such
as those at the Mayo Clinic in Rochester. Indeed, in
our cohort, only 24% of the patients had PSC as a
predisposing etiology, whereas the rate experienced
elsewhere has been approximately 70%. These differ-
ences are difficult to explain but may be due to refer-
ral biases, the differential use of fluorescent in situ
hybridization analysis for diagnosis, or our small size
cohort.
Transplant-related complications did not appear to
be particularly increased, although 1 early death was
noted after an initially uncomplicated course because
of presumed cardiovascular collapse of an unknown
cause. The length of stay after transplantation was
otherwise acceptable (median 5 12.5 days), and no
patients experienced biliary, vascular, or hepatic
insufficiency complications. This compares favorably
with other experiences, which have documented arte-
rial complications in as many as 21% of patients and
portal venous complications in as many as 22% of
patients10 and, as a result, have used donor iliac
artery conduits to the recipient aorta10 (which was
also performed in our protocol).
Tumor responses to neoadjuvant therapy were dem-
onstrated on the basis of an explant analysis, which
showed extensive necrosis of hilar tumors, with 4 of 6
patients demonstrating <0.2-cm foci of residual carci-
nomas and 1 patient having no viable tumor remain-
ing. However, a more detailed analysis using CK7
immunohistochemical analysis showed that this
patient had minute evidence of residual tumor cells.
Although small foci of tumor cells remained, low PIs
and high AIs were noted among the remaining CK71
cells, and they could reflect even greater tumor con-
trol than indicated by routine histological analysis.12
Other experiences have indicated perhaps a greater
tumor eradication rate17; however, direct comparisons
are difficult because of perhaps varying disease bur-
dens at entry and the nonprospective nature of the
pathological evaluation in the current study as well as
previously reported experiences. Nonetheless, it is
hoped that further analysis of tumor explants will
allow us to continue to improve neoadjuvant therapy
while minimizing its toxicity on the basis of this pilot
experience. Unfortunately, our protocol failed to iden-
tify 2 patients with more advanced disease: one with a
positive lymph node and another with a peritoneal
metastasis at the time of transplantation. The isolated
peritoneal implant is difficult to explain, but it may
have been related to unrecognized perforation due to
the numerous complicated biliary interventions
required for this patient. Percutaneous biliary decom-
pression by itself has not been previously shown to be
a risk factor for tumor recurrence after transplanta-
tion.3 Patients with previously known percutaneous,
transduodenal, or operative biopsies of the primary
Figure 3. PIs and AIs of hilar CCAs after neoadjuvant therapy. (A) After patients underwent neoadjuvant therapy and transplantation
(P1-P6), hilar CCAs were subjected to immunohistochemistry for CK7, Ki-67, and TUNEL staining, as shown in Fig. 2 and as described
in the Patients and Methods section. PIs and AIs were calculated as the percentages of Ki-671 CK7 cells and TUNEL1 CK7 cells,
respectively. (B) Results for patients who underwent only resection (no neoadjuvant therapy; P7-P10) are shown for comparison.
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mass were otherwise excluded from this protocol as
well as other reported protocols because of the risk of
tumor seeding.
It must be emphasized that the present study was a
pilot study designed primarily to examine the overall
tolerability and feasibility of using SBRT, capecita-
bine, and transplantation for unresectable hilar CCA.
Although this regimen appears to have acceptable tol-
erability, more patients and a longer follow-up will be
necessary to measure the overall long-term oncologi-
cal benefits of this treatment regimen and to allow
additional comparisons to other currently used regi-
mens. An explant analysis demonstrated evidence of a
pathological response, in that a partial to complete
response was achieved in almost all patients. The
treatment in this pilot study using SBRT allowed a
short radiation treatment interval and led to accepta-
ble rates of protocol completion and listing for trans-
plantation. This regimen, therefore, appears to be a
reasonable multimodality therapy worthy of additional
study as a treatment for unresectable hilar CCA.
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